CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that ...
NeurAxis closed a $5 million stock offering, enhancing funding for its neuromodulation therapies following FDA clearance for pediatric pain treatment. NeurAxis, Inc. has successfully completed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results